Onderzoeker
Jens Tijtgat
- Trefwoorden:Geneeskunde
- Disciplines:Andere basiswetenschappen niet elders geclassificeerd, Kankertherapie, Kankerbiologie
Affiliaties
- Laboratorium Moleculaire Oncologie (Onderzoeksgroep)
Lid
Vanaf22 mrt 2021 → Heden - Medische Oncologie (Departement)
Lid
Vanaf1 aug 2020 → Heden - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf6 jul 2020 → Heden - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf6 jul 2020 → Heden - Faculteit Economische en Sociale Wetenschappen en Solvay Business School (Faculteit)
Lid
Vanaf2 jul 2022 → 18 nov 2022 - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf1 aug 2020 → Heden - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf1 aug 2020 → Heden - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf28 jul 2017 → 25 jun 2020
Publicaties
1 - 10 van 11
- Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients(2022)
Auteurs: Julia Katharina Schwarze, Jens Tijtgat, Gil Awada, Louise Cras, Angela Vasaturo, Christopher Bagnall, Ramses G Forsyth, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, et al.
Pagina's: 1-13 - A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors(2022)
Auteurs: Gil Awada, Julia Katharina Schwarze, Jens Tijtgat, Giuseppe Fasolino, Vibeke Kruse, Bart Neyns
Pagina's: 183-191 - Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial(2022)
Auteurs: Julia Katharina Schwarze, Soizic Garaud, Yanina Jansen, Gil Awada, Valérie Vandersleyen, Jens Tijtgat, Alexandre de Wind, Paulus Kristanto, Teofila Seremet, Karen Willard-Gallo, et al.
- INTRA-CRANIAL ADMINISTRATION OF CTLA-4 AND PD-1 IMMUNE CHECKPOINT-INHIBITING MONOCLONAL ANTIBODIES IN RECURRENT GLIOBLASTOMA PATIENTS: A MULTI-COHORT ADAPTIVE PHASE I CLINICAL TRIAL(2021)
Auteurs: Johnny Duerinck, Wietse Geens, Julia Katharina Schwarze, Cleo Bertels, Jens Tijtgat, Gil Awada, Freya Vaeyens, Louise Cras, Lynn Nijland, Anne-Marie Vanbinst, et al.
Pagina's: 53-53 - Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells(2021)
Auteurs: Jens Tijtgat, Jolien De Munck, Inès Dufait, Julia Katharina Schwarze, Ivan Van Riet, Lorenzo Franceschini, Karine Breckpot, Joeri L Aerts, Bart Neyns, Sandra Tuyaerts
- Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy(2021)
Auteurs: Jens Tijtgat, Julia Katharina Schwarze, Gil Awada, Bart Neyns, Sandrine Aspeslagh
Pagina's: 272-276 - Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma(2021)
Auteurs: Johnny Duerinck, Julia Katharina Schwarze, Gil Awada, Jens Tijtgat, Freya Vaeyens, Cleo Bertels, Wietse Geens, Samuel Klein, Laura Seynaeve, Louise Cras, et al.
- A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT)(2021)
Auteurs: Gil Awada, Julia Katharina Schwarze, Jens Tijtgat, Giuseppe Fasolino, Hendrik Everaert, Bart Neyns
- Sexual violence in medical students and specialty registrars in Flanders, Belgium(2021)
Auteurs: M Geldolf, Jens Tijtgat, L Dewulf, M Haezeleer, Nicolas Degryse, Nicole Pouliart, Ines Keygnaert
- A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab(2021)
Auteurs: Gil Awada, Yanina Jansen, Julia Katharina Schwarze, Jens Tijtgat, Lennert Hellinckx, Odrade Gondry, Sim Vermeulen, Sarah Warren, Kelly A Schats, Pieter-Jan van Dam, et al.
Pagina's: 1-18